Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a report published on Tuesday morning,Benzinga reports. They currently have a $9.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Citius Pharmaceuticals Price Performance

Shares of CTXR stock opened at $4.37 on Tuesday. The company has a market cap of $33.77 million, a P/E ratio of -0.73 and a beta of 1.30. The stock’s 50-day moving average is $5.02 and its 200 day moving average is $11.55. Citius Pharmaceuticals has a 1-year low of $2.44 and a 1-year high of $26.75.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTXR. Point72 DIFC Ltd acquired a new position in shares of Citius Pharmaceuticals during the second quarter valued at about $29,000. XTX Topco Ltd acquired a new position in Citius Pharmaceuticals during the 3rd quarter valued at approximately $47,000. Miller Investment Management LP raised its holdings in shares of Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after buying an additional 49,640 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Citius Pharmaceuticals during the third quarter worth $50,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Citius Pharmaceuticals during the second quarter valued at $69,000. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.